4 | P a ge TABLE OF CONTENTS  
1. INTRODUCTION  ............................................................................................................................................................... 7  
1.1 HEMOPHAGOCYTIC SYNDROME  ......................................................................................................................................................................................... 7 
1.2 RUXOLITINIB  (RUXOLITINIB ) ............................................................................................................................................................ 7 
1.2.1 Preclinical  Data ................................................................................................................................................................... 7  
1.2.2 Clinical  Data .......................................................................................................................................................................... 8  
1.2.3 Clinical Pharmacokinetics  ............................................................................................................................................... 9  
1.3 BACKGROUND  AND  RATIONALE ...................................................................................................................................................................................... 10 
2. OBJECTIVES  .................................................................................................................................................................... 12 
2.1 PRIMARY  OBJECTIVE  ............................................................................................................................................................................................................ 12 
2.1.1 Primary Endpoint  ............................................................................................................................................................. 12 
2.2 SECONDARY  OBJECTIVE (S) ..............................................................................................................................................................12  
3. STUDY  DESIGN .............................................................................................................................................................. 13 
3.1 STUDY DESIGN INCLUDING DOSE ESCALATION  / COHORTS  ............................................................................................................................... 13 
3.2 NUMBER  OF SUBJECTS  ......................................................................................................................................................................................................... 13 
3.3 REPLACEMENT  OF SUBJECTS  ............................................................................................................................................................................................ 13 
3.4 EXPECTED DURATION OF  SUBJECT  PARTICIPATION  ............................................................................................................................................ 13 
3.4.1 Duration  of Therapy  ........................................................................................................................................................  13 
3.4.2 Duration of Follow Up  ..................................................................................................................................................... 14 
4. PATIENT  SELECTION  ................................................................................................................................................... 15 
4.1 INCLUSION  CRITERIA  ............................................................................................................................................................................................................ 15 
4.2 EXCLUSION CRITERIA ........................................................................................................................................................................................................... 15 
4.3 INCLUSION OF WOMEN AND  MINORITIES  ................................................................................................................................................................. 16 
5. REGISTRATION  ............................................................................................................................................................. 17 
6. TREATMENT  PLAN  ....................................................................................................................................................... 18 
6.1 AGENT ADMINISTRATION  .................................................................................................................................................................................................. 18 
6.1.1 Ruxolitinib Administration  ........................................................................................................................................... 18 
6.2 GENERAL CONCOMITANT MEDICATIONS AND SUPPORTIV E CARE  GUIDELINES  ................................................................................... 18 
6.3 DURATION OF FOLLOW  UP ............................................................................................................................................................................................... 19 
7. DOSING DELAYS /  DOSE  MODIFICATIONS .......................................................................................................... 20 
8. ADVERSE EVENTS: LIST AND  REPORTING REQUIREMENTS  ......................................................................... 22 
8.1 ADVERSE EVENTS AND  POTENTIAL RISKS  ................................................................................................................................................................ 23 
8.1.1 Ruxolitinib -related  Adverse  Effects  ........................................................................................................................... 24 
9. DEFINITIONS  .................................................................................................................................................................. 25 
9.1 ADVERSE EVENTS  .................................................................................................................................................................................................................. 25 
9.2 SERIOUS  ADVERSE  EVENTS  .............................................................................................................................................................................................. 26 
9.3 EXPECTEDNESS ........................................................................................................................................................................................................................ 27 
9.4 ATTRIBUTION  ........................................................................................................................................................................................................................... 27 
9.5 REPORTING PROCEDURES FOR ALL ADVERSE  EVENTS  ...................................................................................................................................... 28 
9.5.1 Serious Adverse Event  Reporting  Procedures  ........................................................................................................ 28 
9.5.2 Incyte  Reporting  ................................................................................................................................................................ 28 
9.5.3 FDA  Reporting  .................................................................................................................................................................... 29 
10. PHARMACEUTICAL  INFORMATION  ....................................................................................................................... 31 
5 | P a ge  
 10.1 INVESTIGATIONAL  AGENT  .......................................................................................................................................................................................... 31 
10.1.1  Ruxolitinib  ...................................................................................................................................................................... 31 
11. CORRELATIVE / SPECIAL  STUDIES  ........................................................................................................................ 33 
11.1 BACKGROUND  ................................................................................................................................................................................................................... 33 
11.2 RATIONALE FOR  ANALYSIS  ........................................................................................................................................................................................ 33 
11.3 COLLECTION  OF SPECIMENS  ...................................................................................................................................................................................... 33 
12. STUDY PARAMETERS AND CALENDAR  ................................................................................................................. 33 
12.1 STUDY  PARAMETERS  ..................................................................................................................................................................................................... 34 
12.1.1  Screening  Evaluation  ................................................................................................................................................. 34 
12.2 CALENDAR  .......................................................................................................................................................................................................................... 35 
13. MEASUREMENT  OF EFFECT  ...................................................................................................................................... 36 
13.1 RESPONSE  EVALUATION  .............................................................................................................................................................................................. 36 
13.1.1  Definitions  ...................................................................................................................................................................... 36 
13.1.2  Disease  Parameters  .................................................................................................................................................... 36 
13.1.3  Response  Criteria  ........................................................................................................................................................ 36 
13.1.4  Duration  of Response  ................................................................................................................................................. 37 
14. RECORDS TO BE KEPT / REGULATORY  CONSIDERATIONS  ........................................................................... 37 
14.1 DATA REPORTING  ................................................................................................................................................................................................ ........... 37 
14.2 REGULATORY  CONSIDERATIONS  ............................................................................................................................................................................. 37 
14.2.1  Written  Informed  consent  ....................................................................................................................................... 37 
14.2.2  Subject  Data Protection ............................................................................................................................................ 38 
14.2.3  Acessing Electronic Medical Records for Universityof Michigan Hospital and  Health  
Systems  ................................................................................................................................................................................................... 38 
14.2.4  Retention  of records  ................................................................................................................................................... 38 
14.2.5  Audits  and inspections  .............................................................................................................................................. 38 
14.2.6  Data Safety and  Monitoring Plan  ......................................................................................................................... 39 
15. STATISTICAL  CONSIDERATIONS ............................................................................................................................. 40 
15.1 SAMPLE SIZE ..................................................................................................................................................................................................................... 40 
15.2 ANALYSES ........................................................................................................................................................................................................................... 40 
16. REFERENCES  .................................................................................................................................................................. 42 
17. APPENDIX  A .................................................................................................................................................................... 45 
6 | P a ge   SCHEMA  
Pilot study to determine the efficacy of Ruxolitinib in se condary hemophagocytic syndrome. 
 
STUDY SYNOPSIS  
 
Disease : Secondary Hemophagocytic Syndrome (HPS)  
 
Primary objective: To assess the efficacy of ruxolitinib 15 mg PO twice daily in patients with HPS.  
Primary endpoint: Overall survival at 2 months. 
Secondary objectives:  
1) To assess the safety and tolerability of ruxolitinib in patients with  HPS.  
2) To determine the response rate, duration of response, progression -free survival, and overall survival in 
ruxolitinib treated  subjects.  
Exploratory objectives:  
To assess inflammatory cytokines and markers of T -cell/macrophage activation (i.e. cytokines, sIL -2R, 
sCD163) as predictive biomarkers.  
Inclusion Criteria:  
1) Patients, or their legally authorized representative, must voluntarily provide written IRB-approved 
informed  consent. 
2) Males and females, 18 years of age or older at the time of enrollment.  
3) Patients must meet the diagnostic criteria for HPS (at least 5 of the following): 
-fever  
-splenomegaly 
-cytopenia involving ≥2 cell lines (Hemoglobin <9 g/dL; platelets <100,000/µL; absolute 
neutrophil count <1000/µL)  
-hypertriglyceridemia or hypofibrinogenemia -tissue demonstration of hemophagocytosis 
-low or absent NK cell activity  
-serum ferritin ≥3000 ug/L  
-soluble IL-2 receptor (CD25) >2400 U/mL. 
4) In the investigator’s opinion, the patient has the ability to participate fully in the study and comply with 
all its  requirements.  
Exclusion criteria:  
1) CNS  involvement 
2) Malabsorption  
3) Pregnant or lactating female: all females of child -bearing potential must have a negative serum 
pregnancy test within 7 days of treatment  
4) Has received any prior systemic therapy, excluding corticosteroids, within 7 days of treatment.  
7 | P a ge   5) Estimated creatinine clearance <15mL/min  
6) No active malignancy at the time of enrollment, except nonmelanoma skin cancers or carcinoma in 
situ. Patients with a prior history of malignancy are eligible if their malignancy has been definitely treated 
or is in remission and does not require ongoing adjuvant or cancer- directed  therapies.  
7) Active hep atitis B or hepatitis C or known HIV  infection. 
8) Known (and biopsy- confirmed) liver cirrhosis; or, a reported history of liver cirrhosis with a model for 
end-stage liver disease (MELD) score >20. 
 
1. INTRODUCTION 
1.1 Hemophagocytic  Syndrome  
Hemophagocytic Syndrome (HPS) is a disorder characterized by pathological activation of 
the immune system resulting in a systemic disorder characterized by excessive cytokine 
production and macrophage activation, culminating in cytopenias and evidence of 
hemophagocytosis on tissue specimens. The disorder can be sporadic or familial due to one 
of several mutations and is primarily seen in the pediatric population, with a reported 
incidence of 1 case per 3000 admissions1. The actual incidence in adults is unknown and can 
be rarely sporadic, or secondary to viral infections, malignancy, or autoimmune disease. 
 
HPS is a universally fatal disease if untreated. In adults, the median survival has been reported to 
be less than 2 months if diagnosis and treat ment is delayed2. Adult patients are treated with 
pediatric protocols with early institution of etoposide and steroids and consolidation with allogeneic stem cell transplant in appropriately selected patients if a familial form is identified 
3. 
Other treatment strategies have been attempted, including rituximab4, infliximab5, entaracept6, 
tocilizumab7, and alemtuzumab8. These anecdotal reports highlight the therapeutic potential of 
cytokine-targeted therapies in this disorder. 
 
1.2 Ruxolitinib  
 
1.2.1 Preclinical  Data  
 
Ruxolitinib (INCB018424 phosphate, INC424, ruxolitinib phosphate) represents a novel, 
potent, and selective inhibitor of JAK1 (Janus kinase 1) (inhibition concentration 50% 
[IC50]=3.3 ± 1.2 nM) and JAK2 (IC50=2.8 ± 1.2 nM) with modest to marked selectivity against TYK2 (tyrosine kinase 2) (IC50=19 ± 3.2 nM) and JAK3 (IC50=428 ± 243 nM), 
respectively. Ruxolitinib interferes with the signaling of a number of cytokines and growth 
factors that are important for hematopoiesis and immune function
9-11. 
 
JAK signaling involves recruitment of signal transducers and activators of transcription 
(STATs) to cytokine receptors, activation, and subsequent localization of STATs to the 
nucleus leading to modulation of gene expression. Dysregulation of the JAK- STAT pathway 
has be en associated with several types of cancer and increased proliferation and survival of 
malignant cells12-23. In particular, this pathway may be dysregulated in the majority of 
8 | P a ge   patients with Philadelphia chromosome negative myeloproliferative neoplasms (MPNs, 
including myelofibrosis [MF] and polycythemia vera [PV]), suggesting that JAK inhibition may be efficacious in these diseases.  
 
During the Phase I and Phase II development program, ruxolitinib was assessed in healthy volunteers, subjects with various degrees of renal or hepatic impairment, in patients with rheumatoid arthritis, prostate cancer, multiple myeloma (MM), MF, PV and essential thrombocythemia (ET). Ruxolitinib is currently approved for the treatment of MF/ PV/ET, and is currently under development for the treatment of other hematologic malignancies, and solid tumors. Two pivotal Phase III trials in MF patients have been completed and one in PV patients is ongoing. 
 
 
1.2.2 Clinical Data  
 
Ruxolitinib is a potent, selective ATP -competitive inhibitor of JAK1 and JAK2 kinases, with an 
IC50 of 3.3nM and 2.8nM, respectively. Ruxolitinib inhibits JAK signaling by targeting the cytokines that support transformed cells and are responsible for constitutional symptoms. It 
arrests growth factor signaling by inhibiting downstream STAT phosphorylation. Ruxolitinib has been administered to over 180 healthy volunteers as single, repeat single, or multiple doses of up to 10 days duration. Ruxolitinib has been administered to approximately 450 subjects with MF for periods of up to > 24 months, and over 100 subjects with prostate cancer, multiple myeloma, polycythemia vera or essential thrombocythemia for periods of up to > 24 months. In healthy 
volunteer studies, a transient, reversible decrease in neutrophil count has frequently been seen following dosing, which reverses after 12 to 24 hours off drug, suggestive that the neutropenia may reflect an effect of ruxolitinib blocking IL-6 signaling and causing neutrophil margination on blood vessel walls. In a repeat dose healthy volunteer study, neutropenia of any severity grade was seen in 22% of placebo subjects, 11% of subjects receiving 50 mg qd, 67% of subjects receiving 100 mg qd, 13% of subjects receiving 15 mg bid, 33% of subjects receiving 25 mg bid and 67% of subjects receiving 50 mg bid. Importantly, these neutropenia events were of Grade 1 or Grade 2 severity with a single instance of severe Grade 4 neutropenia that led to discontinuation of study drug in 1 subject receiving ruxolitinib at 50 mg bid (highest dose). The maximum tolerated dose in healthy volunteers was determined to be 25 mg bid and no dose limiting toxicities (DLT) were seen at 100 mg qd. A definitive QT study was carried out in 50 healthy volunteers, evaluating the effects of single doses of 25 mg or 200 mg ruxolitinib compared with placebo and 400 mg moxifloxacin (positive control). The overall conclusion was that there appeared to be no adverse impact on ventricular repolarization (no increase in QTcF) and little change in heart rate, QRS duration, and a slight, non- clinically significant, increase in 
PR interval with the administration of ruxolitinib. This agent is currently FDA approved for the treatment of patients with intermediate to high -risk myelofib rosis, including primary 
myelofibrosis, post-Polycythemia Vera myelofibrosis and Post-Essential Thrombocytopenia myelofibrosis based on pre- clinical activity in cellular assays driven by JAK2 V617F and on the 
results of the phase III studies COMFORT-1 and C OMFORT -2 
24,25. In those trials, the agent 
was continuously dosed at 15- 20mg PO twice daily (BID); currently, depending on platelet 
count, ruxolitinib is FDA approved from 5 mg BID to a maximum dose of 25mg BID. To further demonstrate the tolerability of this agent in other disease settings; pilot studies  have 
9 | P a ge   demonstrated , ruxolitinib was well tolerated in patients with psoriasis and rheumatoid arthritis 
studies 26. Ruxolitinib use has been associated with myelosuppression, thrombocytopenia, and 
anemia in patients with myelofibrosis. Other documented side effects include dizziness, 
headaches, bruising and tranaminitis. 
 
1.2.3 Clinical Pharma cokinetics  
 
Twelve Phase I , five Phase II, and two Phase III clinical studies were conducted to explore the 
clinical pharmacology of ruxolitinib in healthy volunteers and in patients with MF, ET, PV, subjects with renal or hepatic impairment, prostate can cer, MM or rheumatoid arthritis (RA).  
• Oral absorption of ruxolitinib is rapid and nearly complete, with ≥95%  absorption 
indicating high in vivo permeability in the human gastrointestinal tract, consistent with a Biopharmaceutical Classification System (BCS) Class I compound. Mean peak plasma concentrations (Cmax) is achieved 1 -2 h post-dose. 
• The effect of food on ruxolitinib exposure is minimal and is not expected to be clinically 
significant; as a result, the drug may be administered either with or wit hout food. 
• Dose proportional exposure is observed between 5 and 200 mg dose range with linear 
pharmacokinetics  (PK).  
• Plasma protein binding is approximately 97% in vitro. There is moderate distribution to 
organs and tissues with no long- term retention of d rug-related material in preclinical species  and 
limited drug penetration into the central nervous system (CNS) or across the blood- brain  barrier.  
• There is >95% [14C] drug recovery in a mass balance study with 74% and 22% of the 
dose excreted in urine and feces of healthy subjects, respectively. Less than 1% of the administered dose is recovered in urine and feces as unchanged parent drug.  
• The mean terminal elimination half -life is ~3 h with no appreciable accumulation of 
either parent or metabolites with twice daily  dosing. 
• Metabolism is predominantly via the cytochrome P450 isozyme CYP3A4 to yield 
oxygenated and subsequent conjugated metabolites.  
• Oxidative metabolites of ruxolitinib retain pharmacological activity albeit with one half 
to one fifth of the activity of the parent compound. Ex vivo pharmacokinetic/pharmacodynamic 
(PK/PD) analysis indicates that the sum total of 8 active metabolites contribute to 18% of the overall PD activity of  ruxolitinib.  
• When administering ruxolitinib with strong CYP3A4 inhibitors, the total daily  dose 
should be reduced by approximately 50%.  
• No dose adjustment is necessary when co -administering ruxolitinib with strong  CYP3A4 
inducers. 
• In patients with severe [creatinine clearance (Clcr) < 30 mL/min] and moderate renal 
impairment (Clcr = 30 - 49 mL/min), the recommended starting dose based on platelet count should be reduced by approximately 50% to be administered twice a day. Patients on hemodialysis should initiate ruxolitinib with a single dose of 15 mg or 20 mg based on platelet counts with subsequent single doses only on hemodialysis days and following each hemodialysis session. Ruxolitinib doses should be titrated based on individual safety and efficacy.  
• In patients with mild, moderate or severe hepatic impairment, the recommended  starting 
dose based on platelet count should be reduced by approximately 50% with subsequent dose titration based on individual safety and efficacy.  
10 | P a ge   • Baseline elevations in inflammatory markers such as tumor necrosis factor alpha ( TNFα), 
interleukin (IL)-6, and C- reactive protein (CRP) noted in subjects with MF were associated with 
constitutional symptoms such as fatigue, pruritus, and night sweats. Decreases were observed in 
these markers over the 24 weeks of treatment with ruxolitinib, with no evidence that subjects became refractory to the effects of ruxolitinib  treatment.  
 
1.3 Background and  Rationale  
 
Hemophagocytic lymphohistiocytosis (HLH) or hemophagocytic syndrome (HPS) is an 
inflammatory disorder associated with the activation and expansion of reactive (i.e. non- 
clonal) macrophages. Primary HPS is associated with mutations (e.g. ≈50% of familial c ases 
are caused by perforin gene mutations) that culminate in defective natural killer (NK) cell and cytotoxic T-lymphocyte (CTL) degranulation and impaired killing of target cells. In 
these patients, a triggering event (e.g. viral infection) is associated  with immune 
dysregulation that is characterized by the overproduction of proinflammatory cytokines (e.g. 
IL-12 and IFN- γ) and tissue accumulation of activated T -cells and macrophages. 
27-31 These 
immunologic changes are asso ciated with protean clinicopathologic manifestations, 
including: fever, hepatosplenomegaly, hyperferritinemia (due to macrophage activation), 
cytopenias (caused by phagocytosis - “hemophagocytosis”- of hematopoietic cells), 
hypofibrinogenemia, and multi-or gan failure.32 Predominantly observed in children, primary 
HPS is initially managed with supportive care and chemotherapy, but is only curable in 
approximately 60% of children with allogeneic stem cell transplantation.3,33 In contrast to 
primary HPS, secondary HPS is more common in adults and is associated with a variety of 
triggers, including infection (often viral), autoimmunity, or hematologic malignancies 
(commo nly non-Hodgkin lymphomas).32 For many patients, a precipitating cause cannot be 
identified. Apart from disease- specific therapies for patients in which a precipitating cause 
can be identified (e.g. non-Hodgkin lymphoma directed therapies for those with an 
underlying lymphoma), no HPS- specific therapies are currently available for the majority of 
adults with HPS. Therefore, these patients are frequently treated with a regimen originally 
developed for use in children with primary HPS that includes combinations of steroids, 
immunuosuppressive agents (i.e. cyclosporine A), and etoposide. Not surprisingly, secondary 
HPS in adults is associated with high morbidity and mortality. In one of the largest single 
center studies, the overall mortality was 67%, with a median time from diagnosis to death of 
35 (range: 5 -160) days.2 Therefore, improved therapeutic strategies for adults with secondary 
HPS are greatly  needed.  
Both pre- clinical and clinical data hig hlight the central role of proinflammatory cytokines, 
particularly IFN -γ, that are dependent upon the JAK/STAT signaling in HPS pathogenesis. 27- 
31 The disease biology and clinical manifestations associated with HPS are driv en by this 
underlying “cytokine storm”, culminating in T-cell accumulation and macrophage activation. 
Therefore, inhibition of JAK/STAT signaling may represent a novel therapeutic approach. As 
ruxolitinib inhibits upstream Janus kinases (JAK) at nanomolar concentrations, and is well tolerated in myelofibrosis patients (and alleviates signs/symptoms associated with hypercytokinemia), we sought to determine whether it inhibits STAT1 phosphorylation in IFN-γ treated macrophages. Not surprisingly, ruxolitinib (1 μM) was able to inhibit STAT1 
phosphorylation in treated macrophages. Therefore, ruxolitinib represents a novel therapeutic  
11 | P a ge   approach for secondary HPS that has the potential to dramatically change the standard of care 
(and improve outcomes) for these patients. Cytopenias (including thrombocytopenia) observed in HPS are secondary to consumption (“hemophagocytosis”) and cytokine- mediated suppression, and are not secondary to underlying bone marrow “failure”. Therefore, treatment will be initiated at 15 mg po twice daily. 
12 | P a ge   2. OBJECTIVES 
 
 
2.1 Primary  Objective 
 
To assess the efficacy of ruxolitinib 15 mg PO twice daily in patients with HPS.  
 
2.1.1 Primary  Endpoint  
 
Overall survival at two months. 
 
2.2 Secondary  Objective(s)  
 
To assess the safety and tolerability of ruxolitinib in patients with HPS.  
 
To determine the response rate, duration of response, progression-free survival, and overall 
survival in ruxolitinib treated subjects. 
 
2.3 Exploratory Objectives 
 
To assess inflammatory cytokines and markers of T -cell/macrophage activation (i.e. 
cytokines, sIL-2R, sCD163) as predictive biomarkers. 
13 | P a ge   3. STUDY DESIGN 
3.1 Study design including dose escalation / cohorts  
 
Pilot study to determine the efficacy of Ruxolitinib in secondary hemophagocytic syndrome. 
 
 
3.2 Number of  Subjects  
 
Up to 10 patients meeting the inclusion and exclusion criteria will be enrolled into this pilot 
study.  
 
3.3 Replacement of  Subjects  
 
Subjects who do not receive the first dose of study drug will be replaced. 
 
3.4 Expected Duration of Subject  Participation  
 
3.4.1 Duration of Therapy 
 
In the absence of treatment delays or cessation due to adverse events, treatment may continue indefinitely or until one of the following criteria applies: 
 
• Disease progression. 
 
• Intercurrent illness that prevents further administration of treatment.  
 
• The investigator considers it, for safety reasons, to be in the best interest of the patient. The investigator may recommend gradual discontinuation (i.e. ruxolitinib taper) in patients achieving a prolonged response (defined as a PR or CR ≥6 months in duration) . The rate of a ruxolitinib 
taper, and decisions to dose escalate in the setting of recurrent signs/symptoms, are not specified in this protocol, and are at the discretion of the investigator. 
 
• Unacceptable adverse events such as any toxicity or other issue that causes a delay of study drug administration by more than 4  weeks.  
 
• General or specific changes in the patient’s condition render the patient unacceptable for further treatment in the judgment of the investigator. 
 
• Patient decision to withdraw from treatment (partial consent) or from the study (full consent. 
 
14 | P a ge   • Death.  
 
• Sponsor reserves the right to temporarily suspend or prematurely discontinue this study.  
 
15 | P a ge    
The date and reason  for discontinuation must  be documented.  Every  effort  should be made 
to complete the appropriate assessments.  
 
 
3.4.2 Duration of Follow Up  
 
Patients will be followed for efficacy and toxicity for 30 days after treatment has been 
discontinued. Thirty days after treatment discontinuation, progression- free and overall 
survival will be collected every 6 -12 months by a review of the clinical notes from the 
treating investigator or other provider. Patients will be followed for up to five years or until the end of the study or death, whichever occurs first. 
 
Serious adverse events that are still ongoing at the end of the study period will necessitate follow-up to determine the final outcome. Any serious adverse event that occurs after the study period and is considered to be possibly related to the study treatment or study participation will be recorded and reported immediately per IRB & FDA reporting guidelines. 
16 | P a ge   4. PATIENT  SELECTION 
 
A checklist will be used to confirm a patient’s eligibility. The check  list will include the 
inclusion and exclusion  criteria  listed  below, and must be completed  for each patient  and must 
be signed and dated by the treating  physician.  
 
 
4.1 Inclusion  Criteria 
 
Patients must meet all  of the following inclusion criteria to be eligible for enrollment: 
 
1. Patients, or their legally authorized representative, must voluntarily provide written 
IRB-approved informed consent. 
 
2. Males and females, 18 years of age or older at the time of  enrollment.  
 
3. Patients must meet the diagnostic criteria for HPS (at least 5 of the  following):  
-fever  
-splenomegaly 
-cytopenia involving ≥2 cell lines (Hemoglobin <9 g/dL; platelets <100,000/µL; absolute 
neutrophil count <1000/µL)  
-hypertriglyceridemia or hypofibrinogenemia 
-tissue demonstration of hemophagocytosis -low or absent NK cell activity  
-serum ferritin ≥3000 ug/L  
-soluble IL -2 receptor (CD25) >2400 U/mL. 
 
4. In the investigator’s opinion, the patient has the ability to participate fully in the study and comply with all its  requirements. 
 
4.2 Exclusion  Criteria 
 
The presence of any  of the following will exclude a patient from study enrollment.  
 
1. CNS  involvement 
 
2. Malabsorption 
 
3. Known secondary HPS that is otherwise treatable (e.g. non-Hodgkin’s lymphoma). 
 
4. Pregnant or lactating female: all females of child -bearing potential must have a 
negative serum pregnancy test within 7 days of treatment; lactating females must discontinue breast feeding.  
17 | P a ge    
5. Has received any prior systemic therapy, excluding corticosteroids, within 7 days (or 5 
half-lives) of treatment.  
 
6. Estimated creatinine clearance <15  mL/min  
 
7. No active malignancy at the time of enrollment, except nonmelanoma skin cancers or carcinoma in situ. Patients with a prior history of malignancy are  eligible if their 
malignancy has been definitely treated or is in remission and does not require ongoing adjuvant or cancer -directed  therapies.  
8. Active hepatitis B or hepatitis C or known HIV  infection.  
 
9.  Known (and biopsy- confirmed) liver cirrhosis; or, a  reported history of liver cirrhosis 
with a model for end- stage liver disease (MELD) score  >20. 
 
 
 
 
4.3 Inclusion of Women and  Minorities  
 
Both men and women and members of all races and ethnic groups are eligible for this trial. 
18 | P a ge   5. REGISTRATION 
 
All subjects who have been consented are to be registered in an online Database. For those 
subjects who are consented, but not enrolled, the reason for exclusion must be recorded. 
19 | P a ge   6. TREATMENT  PLAN 
 
 
6.1 Study Drug  Administration  
 
Appropriate dose modifications for Ruxolitinib are described in Section 7.0 
 
Reported adverse events and potential risks of Ruxolitinib are described in Section 8.0. 
 
 
 
TREATMENT REGIMEN DESCRIPTION  
 
Agent   
Pre-medicate 
/ Precautions   
Dose   
Route   
Schedule   
Cycle 
Length  
Ruxolitinib  None  15 (mg)  PO in twice 
daily  Days 1 -28 28 days  
 
 
6.1.1 Ruxolitinib Administration  
 
Patients will receive Ruxolitinib at 15 mg twice daily orally either on an empty stomach or 
with food for 4 weeks (28 days) in a 4 week (28 day) cycle. Ruxolitinib will be administered 
in continuous 28- day cycles. For patients unable to ingest tablets, ruxolitinib suspended in 
water may be administered through a nasogastric (NG) or percutaneous endoscopy gastrostomy (PEG) tube.  Tablets  should be suspended (1 tablet  in ~40 mL water)  in water  and 
stirred for 10 minutes and administered within 6 hours of dispersion with an appropriate syringe. The NG or PEG tube should be rinsed with ~75 mL water following administration.  
 
 
Ruxolitinib administration must be at least 1 hour before or after any other medications. 
 
 
6.2 General Concomitant Medications and Supportive Care  Guidelines  
 
Because there is a potential for interaction of Ruxolitinib with other concomitantly administered drugs through the cytochrome P450 system, the ca se report form must capture 
the concurrent use of all other drugs, over-the-counter medications, or alternative therapies. The Principal Investigator should be alerted if the patient is taking any agent known to affect CYP3A4. In patients who concurrently take strong CYP3A4 inhibitors and a platelet count of at least 50,000 the dose of ruxolitinib should be capped at 10 mg twice daily due to the concern for increased serum concentrations of ruxolitinib’s active metabolites. Strong CYP3A4 inhibitors, including grapefruit juice, should be avoided whenever possible. 
20 | P a ge   Patients should receive full supportive care, including transfusions of blood and blood products, 
cytokines, antibiotics, anti- emetics, etc when appropriate.  
 
 
6.3 Duration of Follow  Up 
 
Patients will be followed for toxicity for 30 days after treatment has been discontinued or until death, whichever occurs first. Patients will be followed for survival for up to five years or until the end of the study or death, whichever occurs first. 
 
The clinical course of each event will be followed until resolution, stabilization, or until it 
has been determined that the study treatment or participation is not the cause for a maximum of 6 months. 
 
Serious adverse events that are still ongoing at the end  of the study period will necessitate 
follow-up to determine the final outcome. Any serious adverse event that occurs after the 
study period and is considered to be possibly related to the study treatment or study 
participation will be recorded and reporte d immediately per IRB and FDA reporting 
guidelines. 
21 | P a ge   7. DOSING DELAYS / DOSE  MODIFICATIONS  
 
Ruxolitinib will be dosed twice daily throughout the study. In the event a dose is missed, the 
subject should be instructed to take the next scheduled dos e. 
 
Dose Level  Ruxolitinib 
(BID schedule)   
 CrCl ≥60  CrCl 15 -59 
Level  1 ( starting  dose)  
15 mg   
10 mg 
 
Level -1 ( reduction)  
10 mg   
5 mg 
 
Level -2 (reduction)   
5 mg   
Hold  
 
Event Name  Nausea  
Grade of Event  Management/Next Dose for Ruxolitinib  
≤ Grade  1 No change in dose  
Grade 2  Hold until ≤ Grade 1. Resume at same dose level.  
Grade 3  Hold * until < Grade 2. Resume at one dose level  
lower, if indicated. ** 
Grade 4  Off protocol therapy  
*Patients requiring a delay of >4 weeks should go off protocol therapy.  
**Patients requiring > two dose reductions should go off protocol therapy.  
Recommended management:  antiemetics.  
 
 
Event Name  Vomiting  
Grade of 
Event  Management/Next Dose for Ruxolitinib 
≤ Grade 1  No change in dose  
Grade 2  Hold until ≤ Grade 1. Resume at same dose level.  
Grade 3  Hold* until < Grade 2. Resume at one dose level 
lower, if indicated. ** 
Grade 4  Off protocol therapy  
*Patients requiring a delay of >4 weeks should go off protocol therapy.  
**Patients requiring > two dose reductions  should go off protocol therapy.  
Recommended management: antiemetics; in the event a dose of ruxolitinib is 
vomited, it is recommended that subjects resume ruxolitinib with the next  
scheduled dose.  
22 | P a ge    
 
 
   
 
Event Name  Diarrhea  
Grade of 
Event  Management/Next Dose for Ruxolitinib 
≤ Grade 1  No change in dose  
Grade 2  Hold until ≤ Grade 1. Resume at same dose level.  
Grade 3  Hold* until < Grade 2. Resume at one dose level  
lower, if indicated. ** 
Grade 4  Off protocol therapy  
*Patients requiring  a delay of >4 weeks should go off protocol therapy.  
**Patients requiring > two dose reductions should go off protocol therapy.  
Recommended management: Loperamide antidiarrheal therapy  
Dosage schedule: 4 mg at first onset, followed by 2 mg with each loose 
motion until diarrhea-free for 12 hours (maximum dosage: 16 mg/24 hours) Adjunct anti- diarrheal therapy is permitted and should be recorded when 
used.  
 
 
Event Name  Thrombocytopenia  
Platelet Count  Management/Next Dose for Ruxolitinib 
50,000 -100,000  Level 1 Ruxolitinib  
 
35,000-49,999 Level -1 (reduction) if determined to be secondary to 
Ruxolitinib per the discretion of the investigator or 
PI. 
20,000 -34,999  Level -2 (reduction)  
 
Less than 
20,000 Hold* until platelet count is at least 50,000 then  
resume at one dose level lower if determined to be secondary to Ruxolitinib per the discretion of the 
investigator or PI. Transfuse as needed for bleeds.  
*Patients requiring a delay of >4 weeks should go off protocol therapy.  
**Patients requiring > two do se reductions should go off protocol therapy.  
 
Treatment will be discontinued for any patient that experiences a Grade 4 non -hematologic 
toxicity that is possibly related to ruxolitinib. 
 
Dose adjustments for grades 1 -3 non-hematologic toxicity that is possibly related to 
ruxolitinib will be at the discretion of the investigator or PI.  
23 | P a ge   With the exception of thrombocytopenia (see table above), dose adjustments for grades 1 -4 
hematologic toxicity that is possibly related to ruxolitinib will b e at the discretion of the 
investigator or PI. 
 
8. ADVERSE  EVENTS  
 
The clinical database (safety set based on cut -off for COMFORT -II: 04 -Jan-2011; cut -off for 
COMFORT -I: 02-Nov-2010) in solid tumor and hematologic malignancies consists of 787 
patients treated  in 6 studies evaluating patients with MF (n=679), prostate cancer (n=22), MM 
(n=13), ET and PV (n=73), of whom 617 patients received ruxolitinib: 
• Hematologic events are the most frequently reported adverse events (AEs) and include 
thrombocytopenia and anemia. The majority of these AEs are of Grades 1 -2, seldom led to study 
drug discontinuation (<1% of patients), and can be usually managed through dose reduction or 
interruption. 
• Increased rates of anemia resulted in an increase in packed red blood cell ( PRBC) 
transfusion requirements for some ruxolitinib- treated patients. Platelet transfusions while  on 
ruxolitinib were rare. 
• Biochemistry laboratory abnormalities of alanine aminotransferase (ALT), aspartate 
aminotransferase (AST) and cholesterol were reported. The majority of these increases  were 
Grade 1 or 2. No Grade 4 events were reported.  
• The Phase III safety dataset in MF patients (COMFORT -I, COMFORT -II) shows that it 
is appropriate to individually adjust doses for patients according to their tolerability and  efficacy.  
However, 124 patients (41.2%) required no dose reduction, indicating the starting dose was appropriate for these individuals. Of the 177 patients who had dose reduction, 91 patients (51%) had only one reduction in dose. Interruptions of dosing were less frequent than dose reductions, with 215 patients (71.4%) requiring no dose interruption. Of the 86 patients who had dose interruptions, 59 patients (19.6%) had only one dose interruption. 
• The Phase III data in MF patients (COMFORT -I, COMFORT -II) indicate that the only 
notable imbalances (ruxolitinib versus placebo or best available therapy [BAT]) in AEs related to hemorrhagic events were in Grade 1-2 skin and soft tissue bruising which did not lead to dose reduction or discontinuation. Similarly, the only notable imbalances (ruxolitinib versus placebo or BAT) in AEs related to infections were urinary tract infections and herpes zoster infections. Finally, an imbalance between ruxolitinib and BAT was noted in systolic blood pressure with an increase of 20 mmHg or more from  
baseline in COMFORT -II (31.5% of patients on at least one visit compared with 19.5% of 
the control- treated patients).  
• Cases of tuberculosis have been reported. In addition, one case of progressive multifocal 
leukoencephalopathy has been reported in one patient with myelofibrosis. 
 
The AE profile of the compound has been assessed in 198 healthy volunteers, subjects with various degrees of renal (n=32) or hepatic (n=24) impairment, and in patients with RA (n=59) receivi ng ruxolitinib:  
• AEs were, in general, mild and resolved without interventions. 
24 | P a ge   A thorough QT study was conducted in 50 healthy subjects. There was no indication of a 
QT/QTc prolonging effect of ruxolitinib in single doses up to a supra-therapeutic dose of 200 mg indicating that ruxolitinib has no effect on cardiac repolarization. 
 
The following is a list of AEs (Section 8.1) and the reporting requirements associated with observed AEs (Sections 8.3 and 8.4). 
 
The clinical course of each event will be followed until resolution, stabilization, or until it has 
been determined that the study treatment or participation is not the cause. 
 
Serious adverse events that are still ongoing at the end of the study period will necessitate follow-up to determine the final outcome. Any serious adverse event that occurs within 30 days after the study period and is considered to be possibly related to the study treatment or study participation will be recorded and reported immediately.  
 
8.1 Adverse Events and Potential  Risks  
In a phase III population, the comparison of the control groups to the ruxolitinib patients showed that headache was more frequent in ruxolitinib-treated patients (13.6% vs. 6.0% on placebo and 5.5% on BAT). Most AEs of headache were Grade 1 or 2. Similarly, dizziness (12.0% vs. 6.6% on placebo and 6.8% on BAT) was more frequent in ruxolitinib- treated 
patients, again mostly Grade 1 or 2. When adjusted for patient- year exposure, the differences 
are still present for headache and dizziness . 
 
Weight increase was also more frequent in ruxolitinib -treated patients than in the control 
groups (9.6% vs. 1.3% on placebo and 1.4% on BAT). Although some of these patients had co-reported AEs of edema, many had a past medical history of weight loss an d the weight 
gain usually gradually accumulated over the course of one year of treatment. The majority of weight gain AEs were Grade 1 and 2. It is worth noting that weight gain may be a beneficial effect in patients with MF, given the catabolic nature of the disease and the frequency of weight loss reported as a constitutional symptom.  
 
Other preferred terms with increased frequency in the ruxolitinib arms included bruising (2.6% vs. 1.3% on placebo in COMFORT-I only), contusion (8.6% vs. 5.3% on placebo and 1.4% on BAT), urinary tract infection (7.3% vs. 4.6% on placebo and 2.7% on BAT), herpes zoster (4.0% vs. 0.7% on placebo and 0% on BAT) and flatulence (3.3% vs. 1.3% on placebo and 0% on BAT). 
 
Abdominal pain was more frequent in the control groups than in the ruxolitinib group (43% 
on placebo and 13.7% on BAT vs. 12% on ruxolitinib), as were weight decrease (8.6% on 
placebo and 8.2% on BAT vs. 1% on ruxolitinib), early satiety (8.6% on placebo and 0% on BAT vs. 0.3% on ruxolitinib) and splenic infarction (6.0% on placebo and 0% on BAT vs. 1.0% on ruxolitinib). 
 
For COMFORT -I at the Week 144 interim analysis, for subjects initially randomized to 
ruxolitinib, although the frequency of AEs reported increased as expected with increased 
25 | P a ge   duration of exposure and follow-up, the types of TEAEs reported remained consistent with 
what was reported in the initial analysis. Thrombocytopenia/platelet count decrease remained the most frequently reported AE (58.1%). Anemia/Hgb decreased was reported in 84 subjects (54.2%), which was also an expected effect of ruxolitinib. Among the non- hematologic TEAEs, the most frequently reported TEAE was fatigue (44.5%) followed by diarrhea (35.5%), and peripheral edema (31.0%). 
 
In the ruxolitinib -treated Phase III  population, the overall frequency of AEs requiring dose 
reduction or interruption was 59.8%. This frequency was higher than in the control groups (placebo: 27.2%, BAT: 15.1%). The most frequently reported AEs requiring dose reduction or interruption in ruxolitinib -treated patients were thrombocytopenia (36.9%), platelet count 
decreased (7.6%) and anemia (5.6%). The high frequency for thrombocytopenia is due to protocol-mandated dose reductions and interruptions. Although there were no protocol- specified g uidelines for dose reductions secondary to anemia, some investigators chose to 
reduce a patient’s dose in the setting of anemia to minimize this particular effect of ruxolitinib. The frequency of these AEs was higher than in the control groups. All other A Es 
requiring dose reduction or interruption occurred with a frequency of 1.3% or less in the ruxolitinib -treated patients. For COMFORT -I at the Week 144 analysis for patients initially 
randomized to ruxolitinib 70 patients (45.2%) had at least 1 AE leading to interruption or discontinuation of study drug and 82 (52.9%) had at least 1 AE leading to dose reduction. Thrombocytopenia/platelet count decrease was the most common reason for dose reduction 
or discontinuation. 
 
In the Phase III population, at the initial analysis, there were 34 deaths in total, 27 of which 
were on -treatment deaths: 20 deaths in study COMFORT -I (9 in the ruxolitinib group, 11 in 
the placebo group) and 7 deaths in study COMFORT-II (4 in the ruxolitinib group, 3 in the BAT group). The reasons for death (infections, intestinal perforation, disease progression and events probably due to disease progression, bleedings events) were similar in the ruxolitinib and the placebo groups. 
 
8.1.1 Ruxolitinib -related Adverse Effects  
The following Ruxolitinib side effects are common (occurring in greater than 10%):  
• Cardiovascular: Peripheral edema (22%), elevation in systolic blood 
pressure  
• Central nervous system: Dizziness (15% to 18%), headache (10% to 15%), 
insomnia (12%)  
• Dermatologic: Bruising (19% to 23%) 
• Endocrine & metabolic: Cholesterol increased (17%; grade 2:  <1%)  
• Gastrointestinal: Diarrhea (23%), constipation (13%), nausea (13%), vomiting  (12%)  
26 | P a ge   • Hematologic: Anemia (96%; grade 3: 34%; grade 4: 11%), 
thrombocytopenia due to bone marrow suppression (70%; grade 3: 9%; 
grade 4: 4%), neutropenia (19%; grade 3: 5%; grade 4:  2%) 
• Hepatic: ALT increased (25%; grades 2/3: 2%), AST increased (17%; 
grade 2:  <1%)  
The following Ruxolitinib side effects are less common (occurring in less tha n 
10%): 
• Respiratory: Dyspnea (16%), nasopharyngitis  (16%)  
• Gastrointestinal: Flatulence  (5%)  
• Genitourinary: Urinary tract infection  (9%)  
• Miscellaneous: Herpes zoster infection  (2%)  
 
The following Ruxolitinib side effects are rare:  
 
• Cardiac murmur 
• peripheral  neuropathy 
• weight  gain 
• progressive multifocal leukoencephalopathy (PML)  
• Tuberculosis reactivation  
 
 
 
9. DEFINITIONS  
 
 
9.1 Adverse  Events  
 
An adverse event (AE) is any unfavorable or unintended event, physical or psychological, 
associated with a research study, which causes harm or injury to a research participant as a result of the participant’s involvement in a research study. The event can include abnormal laboratory findings, symptoms, or disease associated with the research study. The event does not necessar ily 
have to have a causal relationship with the research, any risk associated with the research, the research intervention, or the research assessments.  
 
Adverse events may be the result of the interventions and interactions used in the research; 
the colle ction of identifiable private information in the research; an underlying disease, 
disorder, or condition of the subject; and/or other circumstances unrelated to the research or 
any underlying disease, disorder, or condition of the subject. In general, adve rse events that  
27 | P a ge   are at least partially the result of the interventions and interactions used in the research or the 
collection of identifiable private information in the research;would be considered related to the research, whereas adverse ev ents solely related to an underlying disease, disorder, or 
condition of the subject; and/or other circumstances unrelated to the research or any 
underlying disease, disorder, or condition of the subject would be considered unrelated to the 
research.  
 
The significance of an adverse event is used to describe the patient/event outcome or action 
criteria associated with events that pose a threat to a patient’s life or functioning (i.e., moderate, severe or life threatening). Based on the National Cancer Institu te Guidelines for 
the Cancer Therapy Evaluation Program, severity can be defined by the following grades of events:  
 
Grades 1 are mild adverse events. (e.g., minor event requiring no specific medical 
intervention; asymptomatic laboratory findings only; mar ginal clinical relevance)  
 
Grades 2 are moderate adverse events (e.g., minimal intervention; local intervention; non- 
invasive intervention. 
 
Grades 3 are severe and undesirable adverse events (e.g., significant symptoms requiring 
hospitalization or invasi ve intervention; transfusion; elective interventional radiological 
procedure; therapeutic endoscopy or operation).  
 
Grades 4 are life threatening or disabling adverse events (e.g., complicated by acute, life - 
threatening metabolic or cardiovascular complications such as circulatory failure, hemorrhage, sepsis; life –threatening physiologic consequences; need for intensive care or 
emergent invasive procedure; emergent interventional radiological procedure, therapeutic endoscopy or operation). 
 
Grades 5  are fatal adverse event resulting in death.  
 
9.2 Serious Adverse  Events  
A serious adverse event (SAE) is any adverse experience occurring at any dose that results 
in any of the following outcomes: 
• Results in  death.  
• Is a life-threatening adverse experience. The term life -threatening in the definition 
of serious refers to an adverse event in which the subject was at risk of death at the time of the event. It does not refer to an adverse event which hypothetically might 
have caused death if it were more severe.  
• Requires inpatient hospitalization or prolongation of existing hospitalization .  
Any adverse event leading to hospitalization or prolongation of hospitalization will be considered as Serious, UNLESS at least one of the following expectations is met: 
o The admission results in a hospital stay of less than 12 hours OR 
28 | P a ge   o The admission is pre-planned (i.e., elective or scheduled surgery arranged 
prior to the start of the study) OR 
o The admission is not associated with an adverse event (e.g., social 
hospitalization for purposes of respite care.  
However it should be noted that invasive treatment during any hospitalization may 
fulfill the criteria of “medically important” and as such may be reportable as a serious 
adverse event dependent on clinical judgment. In addition where local regulatory authorities specifically require a more stringent definition, the local regulation takes precedent.  
• Results in persistent or significant disability/incapacity . The definition of 
disability is a substantial disruption of a person’s ability to conduct normal life’s 
functions. 
• Is a congenital anomaly/birth defect . 
• Is an important medical event . Important medical events that may not result in 
death, be life-threatening, or require hospitalization may be considered a serious adverse experience when, based upon appropriate medical judgment, they may jeopardize the patient or subject and may require medical or surgical intervention to 
prevent one of the outcomes listed in this definition. Examples of such medical 
events include allergic bronchospasm requiring intensive treatment in an emergency room or at home, blood disease or disorders, or convulsions that do not result in 
inpatient hospitalization, or the development of drug dependency or drug abuse. 
 
9.3 Expectedness  
Adve rse Events can be Expected or Unexpected.  
 
An expected adverse event is an event previously known or anticipated to result from 
participation in the research study or any underlying disease, disorder, or condition of the subject. The event is usually liste d in the package insert, consent form or research protocol. 
 
An unexpected adverse event is an adverse event not previously known or anticipated to result from the research study or any underlying disease, disorder, or condition of the subject. 
 
9.4 Attribution  
Attribution is the relationship between an adverse event or serious adverse event and the study drug. Attribution will be assigned as follows: 
 
• Definite – The AE is clearly related  to the study drug. 
• Probable – The AE is likely related  to the study drug. 
• Possible – The AE may be related  to the study drug.  
• Unlikely – The AE is doubtfully related to the study drug.  
• Unrelated – The AE is clearly NOT related  to the study drug.  
29 | P a ge   9.5 Reporting Procedures for All Adverse  Events  
 
All participating investigators will assess the occurrence of AEs throughout the subject’s 
participation in the study. Subjects will be followed for toxicity for 30 days after treatment has been discontinued or until death, whichever occurs first. The clinical course of each event will be followed until resolution, stabilization, or until it has been determined that the study treatment or participation is not the cause.  
 
The investigator is responsible for ensuring that all adverse events observed by the investigator or reported by the subject which occur after the subject has been started on the investigational agent are fully recorded in the subject’s case report form, subject’s medical records, and/or any other institutional requirement. Source documentation must be available 
to support all adverse events. 
 
A laboratory test abnormality considered clinically relevant (e.g., causing the subject to withdraw from the study), requiring treatment or causing apparent clinical manifestations, or 
judged relevant by the investigator, should be reported as an adverse event. 
 
The investigator will provide the following for all adverse events: 
• Description of the event  
• Date of onset and  resolution 
• Grade of  toxicity  
• Attribution of relatedness to the investigational agent 
• Action taken as a result of the event  
• Outcome of event  
 
In this study, descriptions and grading scales found in the NCI Common Terminology Criteria 
for Adverse Events (CTCAE) version 4.03 available at http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm will be utilized for AE reporting.  
 
 
9.5.1 Serious Adverse Event Reporting  Procedures  
 
Serious adverse events that occur beginning after the subject  has been started on the 
investigational agent or within 30 days of the last dose of treatment must be reported to the Sponsor Investigator. Serious adverse events will be reported to the IRBMED according to their reporting guidelines and to the FDA as detailed in Section 9.5.3. 
 
 
 
9.5.2 Incyte Reporting  
30 | P a ge   If the SAE is not previously documented in the package insert for the study drug (new 
occurrence) and is thought to be related to the study drug, a manufacturer’s associate may 
urgently require further information from the Investigator or Sponsor for repor ting to Health 
Authorities. Incyte will be notified within 24hrs of any IND safety event and will receive a copy 
of the initial and follow up IND Adverse Event reports within 48hrs of submission to regulatory authorities. This will be submitted to the following email address: IncytePhVOpsIST@incyte.com
 
 
9.5.3 FDA  Reporting  
 
The University of Michigan Sponsor Investigator, Ryan Wilcox, as holder of the IND, will be 
responsible for all communication with the FDA. In accordance with 21 CFR 312.32, The University of Michigan Sponsor Investigator, Ryan Wilcox is responsible for notifying the FDA 
of SAEs that are serious, unexpected (not listed in the package insert) and judged to be related (i.e., possible, probable, definite) to the study drug. Events meeting the following criteria need 
to be submitted to the FDA as Expedited IND Safety Reports. 
 
7 Calendar Day IND Safety Report 
Any unexpected fatal or life- threatening suspected adverse event represent especially imp ortant 
safety information and, therefore, must be reported more rapidly to FDA (21 CFR 312.32(c)(2)). 
Any unexpected fatal or life-threatening suspected adverse event must be reported to FDA no later than 7 calendar days after the University of Michigan Sp onsor Investigator, Ryan Wilcox, 
obtains initial receipt of the information (21 CFR 312.32(c)(2)). The University of Michigan Sponsor Investigator, Ryan Wilcox, will complete a Medwatch Form FDA 3500A and notify the FDA by telephone or facsimile transmission with the assistance of the Michigan IND/IDE Assistance Program (MIAP).  
 
15 Calendar Day IND Safety Report 
The timeframe for submitting an IND safety report to FDA is no later than 15 calendar days after 
the University of Michigan Sponsor Investigator de termines that the suspected adverse event or 
other information qualifies for reporting (21 CFR 312.32(c)(1)). This includes any serious, unexpected adverse events considered reasonably or possibly related to the investigational agent. The University of Michigan Sponsor Investigator, Ryan Wilcox will complete a CTO standard SAE Form and notify the FDA by telephone or facsimile transmission with the assistance of MIAP. If FDA requests any additional data or information, the University of Michigan Sposor Inves tigator must submit it to FDA as soon as possible, but no later than 15 calendar days after 
receiving the request (21 CFR 312.32(c)(1)(v)). 
 
Follow- up IND Safety Report  
Any relevant additional information that the University of Michigan Sponsor Investigator obtains that pertains to a previously submitted IND safety report must be submitted to FDA as a Follow- up IND Safety Report without delay, as soon as the information is available (21 CFR 312.32(d)(2)). The University of Michigan Sponsor Investigator, Ry an Wilcox, will maintain 
records of its efforts to obtain additional information. 
31 | P a ge      
    
 
 
 
IND Annual Reports  
 
A summary of all IND safety reports submitting during the previous year will be reported to the 
FDA in the annual report by The University of Michigan Sponsor Investigator, Ryan Wilcox, as holder of the IND. 
Reporting Serious Problems to FDA 
Medwatch Form FDA 3500A: 
http://www.fda.gov/Safety/MedWatch/HowToReport/DownloadForms/default.htm  
Telephone: 1 -800-332-1088 
Fax: 1-800- FDA -0178 
32 | P a ge   10. PHARMACEUTICAL  INFORMATION 
 
A list of the adverse events and potential risks associated with the investigational or 
commercial agents administered in this study can be found in Section 8. 
 
10.1 Investigational Agent  
 
Agents are listed in alphabetical order.  
 
10.1.1  Ruxolitinib  
 
Chemical  Name:  (R)-3-(4-(7H-pyrrolo[2,3 -d]pyrimidin -4-yl)-1H-pyrazol -1-yl)-3- 
cyclopentylpropanenitrile phosphate 
Other Names:  Ruxolitinib  
 
Classification:  selective JAK1 and JAK2  inhibitor 
 
Molecular Formula:  
 
Mode of Action: Inhibits Janus Associated Kinases (JAKs) JAK1 and  JAK2  
which mediate the signaling of a number of cytokines and growth factors that are important for hematopoiesis and immune function 
 
Metabolism:  In vitro studies suggest that CYP3A4 is the major enzyme  
responsible for metabolism of ruxolitinib. Ruxolitinib is the predominant entity in humans representing approximately 60% of the drug- related material in circulation. Two major and active 
metabolites were identified in plasma of healthy subjects representing 25% and 11% of parent AUC. These two metabolites have one-fifth and one-half of ruxolitinib’s pharmacological activity, respectively. The sum total of all active 
metabolites contributes 18% of the overall pharmacodynamics of ruxolitinib. 

33 | P a ge   Product  description : Ruxoliti nib (ruxolitinib) Tablets are for oral administration.  The 
tablet contains ruxolitinib phosphate equivalent to 5 mg of 
ruxolitinib free base together with Microcrystalline cellulose, lactose monohydrate, magnesium stearate, colloidal silicon dioxide, sodium starch glycolate, povidone and hydroxypropyl cellulose.  
 
Solution preparation:  Not applicable 
 
Storage requirements : Store at room temperature 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C and 30°C (59°F and 86°F) 
 
Stability:  Not applicable  
 
Route of administration: Ruxolitinib is dosed orally and can be administered with or 
without food. 
 
Drug Procurement: Ruxolitinib will be supplied for this study by Incyte. Once notified by Incyte  of IST support, Principal  Investigator or study staff will contact  Incyte’s  Medical  Affairs 
Operations and Program Manager or Medical Science Liaison to inform them of the amount of study drug needed to conduct the study. The Medical Affairs Operations and Program Manager at Incyte will generate a requ isition for Investigational Product (IP) supplies and 
manage shipments through a third party vendor. 
 
 
Drug Accountability : The investigator or designated study personnel are responsible for 
maintaining accurate dispensing records of the study drug. All st udy 
drugs must be accounted for, including study drug accidentally or deliberately destroyed. Under no circumstances will the investigator allow the investigational drug to be used other than as directed by the protocol. Drug storage, drug dispensing, and drug accountability will be performed by the UM Research Pharmacy. Final drug accountability will be made to Incyte. Drug Destruction : At the 
completion of the study, there will be a final reconciliation of drug shipped, drug consumed, and drug remaining. This reconciliation will be logged on the drug reconciliation form, signed and dated. Any discrepancies noted will be investigated, resolved, and documented prior to return or destruction of unused study drug. Drug destroyed on site will be documented in the study files. Final drug accountability certificate will be provided to Incyte at the end of the study.  
34 | P a ge   11. CORRELATIVE / SPECIAL  STUDIES  
11.1 Background  
 
Hemophagocytic syndrome is driven by inflammatory cytokines, including interferon- γ, that 
culminate in STAT1 phosphorylation, activated T-cell accumulation, and macrophage 
activation.  
 
11.2 Rationale for  Analysis 
 
We will utilize immunofluorescent staining (by flow cytometry) to test the hypothesis that ruxolitinib inhibits Stat1 activation in HPS. We will evaluate the expression of Stat1 and pStat1 in peripheral blood T-cells and monocytes pre- and post-treatment. The post- treatment analysis will be conducted 7 (+/ - 3) days following treatment initiation. T -cell (sIL - 
2R) and macrophage (soluble CD163) activation markers will be serially analyzed by ELISA in patient plasma. Plasma samples will by obtained weekly and cryopreserved for analysis of relevant cytokines (including interferon- γ) by ELISA. We will test the hypothesis that 
ruxolitinib decreases inflammatory markers (e.g. soluble CD163) associated with macrophage activation.  
 
11.3 Collection of  Specimens  
 
Research blood samples (≈20 mL) will be obtained prior to treatment, and every 7 days (+/ -2 
days) thereafter.  
 
Handling of Specimens 
 
All specimens are to be shipped to the Wilcox laboratory at the address below. Lab 
personnel will re- label the specimen using a code specific for this trial. Peripheral blood 
mononuclear cells will be isolated by density centrifugation and viably frozen using 
laboratory standard operating procedures. Platelet-poor plasma will be isolated using laboratory standard operating procedures and cryopreserved. 
 
Wilcox laboratory  
1400 E. Medical Center Drive 4431 Cancer Center Ann Arbor, MI 48109 
 
 
12. STUDY PARAMETERS AND  CALENDAR  
35 | P a ge   12.1 Study  Parameters  
 
12.1.1  Screening  Evaluation 
 
Screening studies and evaluations will be used to determine the eligibility of each subject for 
study inclusion. All evaluations must be completed no longer than 14 days prior to administration  of protocol therapy. 
 
• Informed  Consent 
• Medical History  
• Complete physical examination  
• Vital signs including: blood pressure, pulse, respiratory rate, weight and temperature  
• Concomitant Medications Assessment including prescription and herbal supplements 
• Laboratory  Studies: 
• Complete Blood Count (CBC) with differential and platelets.  
• Serum Chemistries: albumin, alkaline phosphatase, total bilirubin, 
bicarbonate, BUN, calcium, chloride, creatinine, glucose, potassium, total 
protein, SGOT [AST], SGPT [ALT], sodium. 
• ß-HCG for women of childbearing potential at time of study  entry  
• Ferritin  
• Lipids (Triglycerides)  
• Fibrinogen 
• Soluble IL -2 receptor  
• NK cell  activity  
36 | P a ge    
12.2 Calendar  
 
 
  
Enrollment  
(within 14 days 
of treatment)   
Pre-treatment  
(within 48 hours 
of treatment)  Weekly  
(weeks  1-5)4 
(beginning day 
7, +/- 2 days)   
q14 days 
+/- 3 days 
(weeks 6 -12)4  
q28 days 
+/- 3 days 
(>12 weeks)4 
Informed consent  X     
H&P (including medication review)  X X X X X 
CBC1 X X X X X 
Serum Chemistries (including  
AST/ALT)  X X X X X 
Pregnancy test5 X     
Ferritin  X X X X X 
Lipids  X X X X  
Fibrinogen  X X X X  
sIL-2 Receptor  X X X X  
NK cell activity2 X X X   
Research blood draw3  X X   
Collect Adverse Events  X X X X X 
1Performed at least every 72 hours for weeks 1 -5 of treatment. 2May be performed every 7 -14 
days. If total lymphocytes are insufficient to measure NK cell activity during enrollment, 
repeat testing is not required. 3Four heparin tubes (≈20 mL total volume) will be collected. 
Peripheral blood mononuclear cells and platelet-poor plasma will be obtained and cryopreserved for ancillary studies. Research blood draws will cease 14 days after a CR is achieved or after 5 weeks of treatment, whichever comes first. 
4Study procedures required for 
response assessments and toxicity monitoring will be performed every two weeks (Bi- weekly) 
for patients who remain on treatment >6 weeks. For patients who remain on treatment >12 weeks, the following procedures will be performed monthly: H&P, CBC, serum chemistries, ferritin, and adverse events. 
5Pregnancy testing will be performed every 6 weeks (+/ - 7 days) 
in women of child -bearing potential.  
37 | P a ge   13. MEASUREMENT OF EFFECT  
 
13.1 Response  evaluation  
 
13.1.1  Definitions  
 
Evaluable for toxicity.  All patients will be evaluable for toxicity from the time of their first 
treatment with Ruxolitinib . 
 
Evaluable for objective response. Only those patients who received at least 7 days of therapy, 
and have had their disease re- evaluated will be considered evaluable for response. These 
patients will have their response classified according to the definitions stated below. 
 
 
13.1.2  Disease Parameters  
• Fever  
• Splenomegaly (by physical examination or radiographic imaging).  
• Cytopenias involving ≥2 cell  lines  
• Ferritin  
• Triglycerides  
• Fibrinogen 
• Soluble IL -2 receptor  
• NK cell  activity  
 
13.1.3  Response  Criteria  
 
Evaluation of Response 
 
Response  Evaluation of Target Lesions  
 
Complete Response (CR) Complete normalization of all quantifiable signs and  
laboratory abnormalities included in the diagnostic criteria 
for HPS.  
Partial Response (PR)  At least a 25% improvement in two or more quantifiable  
signs/laboratory markers.  
Progressive Disease (PD)  At least a 50% worsening in two or more quantifiable  
signs/laboratory markers.  
Stable Disease (SD)  Neither sufficient improvement to qualify for CR/PR,  
nor sufficient worsening to qualify for PD.  
38 | P a ge   13.1.4  Duration of Response 
 
Duration of overall response: The duration of overall response is measured from the time 
measurement criteria are met for CR or PR (whichever is first recorded) until the first date 
that recurrent or progressive disease is objectively documented. The duration of overall CR is measured from the time criteria are first met for CR until the first date that pr ogressive 
disease is objectively documented. 
 
Duration of stable disease : Stable disease is measured from the start of the treatment until 
the criteria for progression are met.  
 
 
14. RECORDS TO BE KEPT / REGULATORY  CONSIDERATIONS  
 
Adverse event lists, guidelines, and instructions for AE reporting can be found in Section 8.0 
(Adverse Events: List and Reporting Requirements). 
 
14.1 Data  Reporting  
 
The Velos Database will be utilized, as required by the UNIVERSITY OF MICHIGAN 
COMPREHENSIVE CANCER CENTER, to pro vide data collection for both accrual entry 
and trial data management. Velos is designed with the capability for study setup, activation, tracking, reporting, data monitoring and review, and eligibility verification. This study will utilize electronic Case  Report Form completion in the Velos database. A calendar of events 
and required forms are available in Velos. 
 
14.2 Regulatory Considerations  
 
The study will be conducted in compliance with ICH guidelines and with all applicable federal (including 21 CFR parts 56 & 50), state or local laws. 
 
14.2.1  Written Informed  consent  
Provision of written informed consent must be obtained prior to any study-related procedures. 
The Principal Investigator will ensure that the subject is given full and adequate oral and written 
information about the nature, purpose, possible risks and benefits of the study as well as the 
subject’s financial responsibility. Subjects must also be notified that they are free to discontinue from the study at any time. The subject should be given the opportunity to ask questions and allowed time to consider the information provided. 
The original, signed written Informed Consent Form must be kept with the Research Chart in 
conformance with the institution’s standard operating procedures. A copy of the s igned written 
Informed Consent Form must be given to the subject. 
39 | P a ge   14.2.2  Subject Data Protection  
In accordance with the Health Information Portability and Accountability Act (HIPAA), a 
subject must sign an authorization to release medical informatio n to the manufacturer and/or 
allow the manufacturer, a regulatory authority, or Institutional Review Board access to subject’s medical information that includes all hospital records relevant to the study, including subjects’ medical history.  
 
14.2.3  Accessing Electronic Medical Records for University of Michigan Hospital and 
Health  Systems  
 
This study will access electronic medical records systems to obtain medical information for 
the subjects enrolled to this study. 
 
In order to insure patient safety, investigators and study personnel must have up- to-the- 
minute health information for subjects enrolled to this study. Therefore, electronic medical records must be utilized to obtain medical information in a timely manner.  
 
The following electronic systems will be us ed: MiChart to access scheduling information; 
MiChart and Careweb to access lab results and physician notes; MiChart and Careweb as necessary to locate archived medical records; PACS to access radiological imaging results.  
 
Access to these systems is required for the life of this research study.  
 
Information obtained from electronic systems will be copied into the University of Michigan Cancer Center Clinical Trials Unit research chart and/or printed (lab results, physician notes, etc.) and stored in the research chart. Research charts are kept secure and destroyed according to UH policy. 
 
Study data will be obtained by the PI, co -investigators, study coordinator, and/or data 
manager for this study via password-protected login. All study personnel involved in this research will adhere to the UH policies regarding confidentiality and Protected Health Information. 
 
14.2.4  Retention of records  
 
The Principal Investigator of The UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER supervises the retention of all documentation of adverse events, records of study drug receipt and dispensation, and all IRB correspondence for as long as needed to comply with national and international regulations. No records will be destroyed until the Principal Investigator confirms destruc tion is permitted.  
 
14.2.5  Audits and  inspections  
Authorized representatives of the manufacturer, a regulatory authority, an Independent Ethics 
Committee (IEC) or an Institutional Review Board (IRB) may visit the Center to perform audits  
40 | P a ge   or inspections, including source data verification. The purpose of an audit or inspection is to 
systematically and independently examine all study -related activities and documents to 
determine whether these activities were conducted, and data were recorded, analysed,  and 
accurately reported according to the protocol, Good Clinical Practice (GCP), and any applicable 
regulatory requirements. 
14.2.6  Data Safety and Monitoring Plan  
 
This protocol will adhere to the policies of the UNIVERSITY OF MICHIGAN 
COMPREHENSIVE CANCER CENT ER Data and Safety Monitoring Plan in accordance with 
NCI regulations.  
 
This trial will be monitored in accordance with the NCI approved University of Michigan 
Comprehensive Cancer Center Data and Safety Monitoring Plan. The study specific Data and Safety Monitoring Committee (DSMC), consisting of the protocol investigators, data manager or 
designee, and other members of the study team involved with the conduct of the trial, will meet quarterly  or more  frequently  depending on the activity  of the protocol. The discussion will include 
matters related to the safety of study participants (SAE/UaP reporting), validity and integrity of the data, enrollment rate relative to expectations, characteristics of participants, retention of participants, adherence to the protocol (potential or real protocol deviations) and data completeness. At the regular DSMC meetings, the protocol specific Data and Safety Monitoring Report form will be completed. The report will be signed by the Principal Investigator or by one of the co-investigators. Data and Safety  Monitoring Reports will be submitted  to the University of 
Michigan Comprehensive Cancer Center Data and Safety Monitoring Board (DSMB) on a quarterly basis for independent review.  
41 | P a ge    
 
15. STATISTICAL  CONSIDERATIONS  
 
 
15.1 Sample  Size 
We will accrue and treat 10 patients on this pilot trial. We expect a 2 -month survival rate 
approximating 15% in patients meeting the inclusion criteria with current standard of care. As 
we believe ruxolitinib may be highly active in this dis ease and change the current treatment 
paradigm, we believe the majority of treated patients will be alive at 2 months. Therefore, if 4 or more patients are alive 2 months following diagnosis, this would provide sufficient evidence to pursue ruxolitinib in an expanded cohort of patients in a future study. This design has 80% 
power to detect a survival rate of 60% versus an estimated survival rate of 15% using a 2-sided 
test, with 5% type 1error. The operating characteristics for design are given in the table below for 
a range of true values for the probability of survival at 2 months, with at least 4 responders the critical  value.  
 
Probability of survival at 2 months following  
  diagnosis   Probability therapy is deemed effective  
0.05  0.010  
0.15  0.050  
0.25  0.228  
0.35  0.488  
0.45  0.738  
0.55  0.901  
0.65  0.978  
 
 
15.2 Analyses 
 
Primary:  
The primary analysis is the count of patients alive after 2 months since study entry. If 4 or more patients are alive at the 2 months assessment, the null hypothesis of a 15% survival probability at 2 months will be rejected in favor or our alternative hypothesis of a 60% survival probability. Ninety- five percent confidence intervals will be constructed based  upon 
the exact binomial confidence interval. No loss- to-follow-up or censoring is expected prior 
to the study’s primary endpoint assessment.  
Secondary:  
There are no formal response criteria for secondary HPS. Therefore, efficacy assessments 
(including appropriate laboratory studies) will be performed weekly (weeks 1-5), and every two weeks (weeks 6 -12), and monthly (after 12 weeks), and responses determined as 
previously reported in a retrospective study.
8 Briefly, a complete response is defined as  
42 | P a ge   complete normalization of all quantifiable symptoms and laboratory abnormalities (described 
in the diagnostic criteria for HPS, above). A partial response is defined as at least a 25% improvement in two or more quantifiable symptoms/laboratory markers following the initiation of treatment. The best overall response is the best response recorded from the start of the treatment until disease progression/recurrence 
Follow- up time will be calculated from the first administration of ruxolitinib, until death for 
OS or until disease- progressio n or death for PFS. Patients lost to follow-up will be censored 
on the date of their last known clinical assessment. Specifically for DOR, only patients 
having at least a PR to therapy are evaluable. Duration will be calculated from the date of the determi nation of partial response or better until the date of progression, death, or 
additional non-protocol therapy. Again, for patients lost to follow-up, duration will be censored at the time of last clinical assessment. The count and percentage of the number having an objective response (CR, CRu, or PR) will be reported along with confidence intervals. Product- limit estimates of Kaplan and Meier will be used to estimate OS, PFS, and 
DOR. The likelihood of loss to follow- up is expected to be extremely low.  
Exploratory: 
Plasma will be obtained before treatment and weekly thereafter, and cryopreserved for 
future corollary studies (e.g. cytokine
27,28 and soluble CD163 determination34). We will 
compare cytokine, soluble IL -2R and soluble CD163 levels pre-treatment and post 
treatment. We seek to correlate change in expression (decrease) with positive response 
(complete vs. partial vs. stable) to therapy via regression models that appropriately account for the serial correlation of repeated measures within a patient. Inference from these models would be hypothesis generating. 
43 | P a ge   16. REFERENCES  
 
1. Allen CE, Yu X, Kozinetz CA, McClain KL. Highly elevated ferritin levels and 
the diagnosis of hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer . 
2008;50(6):1227- 1235.  
2. Shabbir M, Lucas J, Lazarchick J, Shirai K. Secondary hemophagocytic 
syndrome in adults: a case series of 18 patients in a single institution and a review of 
literature. Hematol Oncol . 2011;29(2):100- 106. 
3. Henter JI, Samuelsson -Horne A, Arico M, et al. Treatment of hemophagocytic 
lymphohistiocytosis with HLH -94 immunochemotherapy and bone marrow 
transplantation. Blood . 2002;100(7):2367- 2373.  
4. So MW, Koo BS, Kim YJ, Kim YG, Lee CK, Yoo B. Successful rituximab 
treatment of refractory hemophagocytic lymphohistiocytosis and autoimmune hemolytic anemia associated with systemic lupus erythematos us. Mod Rheumatol . 
2013.  
5. Henzan T, Nagafuji K, Tsukamoto H, et al. Success with infliximab in treating 
refractory hemophagocytic lymphohistiocytosis. Am J Hematol . 2006;81(1):59- 61. 
6. Cortis E, Insalaco A. Macrophage activation syndrome in juvenile idiopathi c 
arthritis. Acta Paediatr Suppl . 2006;95(452):38- 41. 
7. Teachey  DT, Rheingold SR, Maude  SL, et al. Cytokine release syndrome after 
blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine- directed therapy. Blood . 2013;121(26):5154- 5157.  
8. Marsh RA, Allen CE, McClain KL, et al. Salvage therapy of refractory 
hemophagocytic lymphohistiocytosis with alemtuzumab. Pediatr Blood Cancer . 
2013;60(1):101- 109. 
9. Mesa RA. Ruxolitinib, a selective JAK1 and JAK2 inhibitor for the treatment of 
myeloproliferative neoplasms and psoriasis. IDrugs . 2010;13(6):394 -403. 
10. Verstovsek S, Kantarjian H, Mesa RA, et al. Safety and efficacy of 
INCB018424, a JAK1 and JAK2 inhibitor,  in myelofibrosis. N Engl J Med. 
2010;363(12):1117- 1127.  
11. Quintas -Cardama A, Vaddi K, Liu P, et al. Preclinical characterization of the 
selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood . 2010;115(15):3109- 3117.  
12. Catlett -Falcone R, Landowski TH, Oshiro MM, et al. Constitutive activation of 
Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity . 1999;10(1):105- 115. 
13. Palmer  J, Goggins  T, Broadwater  G, et al. Early  post transplant  (F-18) 2-fluoro- 
2-deoxyglucose positron emission tomography does not predict outcome for patients 
undergoing auto- SCT in non- Hodgkin and Hodgkin lymphoma. Bone Marrow 
Transplant . 2011;46(6):847- 851. 
14. Casulo C, Schoder H, Feeney J, et al. 18F -fluorodeoxyglucose positron 
emission tomography in the staging and prognosis of T cell lymphoma. Leuk 
Lymphoma. 2013;54(10):2163- 2167.  
15. Furey ML, Pietrini P, Alexander GE, Schapiro MB, Horwitz B. Cholinergic 
enhancement  improves  performance on worki ng memory  by modulating  the functional  
44 | P a ge   activity in distinct brain regions: a positron emission tomography regional cerebral 
blood flow study in healthy humans. Brain Res Bull. 2000;51(3):213- 218. 
16. Murphy DG, DeCarli C, McIntosh AR, et al. Sex differences in human brain 
morphometry and metabolism: an in vivo quantitative magnetic resonance imaging 
and positron emission tomography study on the effect of aging. Arch Gen Psychiatry. 
1996;53(7):585- 594. 
17. Mentis  MJ, Weinstein  EA, Horwitz  B, et al. Abnormal  brain  glucose metabolism 
in the delusional misidentification syndromes: a positron emission tomography study 
in Alzheimer disease. Biol Psychiatry . 1995;38(7):438- 449. 
18. Grady CL, Haxby JV, Horwitz B, et al. Dissociation of object and spatial vision 
in human extrastriate cortex: age- related changes in activation of regional cerebral 
blood flow measured with [(15) o]water and positron emission tomography. J Cogn 
Neurosci . 1992;4(1):23 -34. 
19. McNamara D, Horwitz B, Grady CL, Rapoport SI. Topographical analysis of 
glucose metabolism,  as measured  with positron  emission  tomography,  in dementia  of 
the Alzheimer type: use of linear histograms. Int J Neurosci . 1987;36(1- 2):89- 97. 
20. Miller TP, Dahlberg S, Cassady JR, et al. Chemotherapy alone compared with 
chemotherapy plus radiotherapy for localized intermediate- and high -grade non- 
Hodgkin's lymphoma. N Engl J Med . 1998;339(1):21- 26. 
21. Miura  SA, Schapiro MB, Grady  CL, et al. Effect of gender  on glucose utilization 
rates in healthy humans: a positron emission tomography study. J Neurosci Res . 
1990;27(4):500- 504. 
22. Horning  SJ, Weller  E, Kim K, et al. Chemotherapy  with or without  radiotherapy 
in limited -stage diffuse aggressive non- Hodgkin's lymphoma: Eastern Cooperative 
Oncology Group study 1484. J Clin Oncol. 2004;22(15):3032- 3038.  
23. Mangel J, Leitch HA, Connors JM, et al. Intensive chemotherapy and 
autologous stem -cell transplantation plus rituximab is superior to conventional 
chemotherapy  for newly  diagnosed advanced stage  mantle- cell lymphoma:  a matched 
pair analysis. Ann Oncol . 2004;15(2):283- 290. 
24. Liu Z, Long Y, Zhang Y, et al. Nuclear p27 expression confers a favorable 
outcome for nasopharyngeal carcinoma patients. Dis Markers . 2013;35(6):925- 932. 
25. Yang T, Zhang XB, Zheng ZM. Suppression of KIF14 expression inhibits 
hepatocellular carcinoma progression and predicts favorable outcome. Cancer Sci . 
2013;104(5):552- 557. 
26. Leitch HA, Gascoyne RD, Chhanabhai M, Voss NJ, Klasa R, Connors JM. 
Limited -stage mantle- cell lymphoma. Ann Oncol . 2003;14(10):1555- 1561.  
27. Canna SW, Behrens EM. Making sense of the cytokine storm: a conceptual 
framework for understanding, diagnosing, and treating hemophagocytic syndromes. Pediatr Clin North Am . 2012;59(2):329- 344. 
28. Fujiwara F, Hibi S, Imashuku S. Hypercytokinemia in hemophagocytic 
syndrome. Am J Pediatr Hematol Oncol . 1993;15(1):92- 98. 
29. Jordan MB, Hildeman D, Kappler J, Marrack P. An animal model of 
hemophagocytic lymphohistiocytosis (HLH): CD8+ T cells and interferon gamma are essential for the disorder. Blood . 2004;104(3):735- 743. 
45 | P a ge   30. Sato K, Misawa N, Nie C,  et al. A novel animal model of Epstein- Barr virus - 
associated hemophagocytic lymphohistiocytosis in humanized mice. Blood . 
2011;117(21):5663- 5673.  
31. Zoller EE, Lykens JE, Terrell CE, et al. Hemophagocytosis causes a 
consumptive anemia of inflammation. J Exp  Med. 2011;208(6):1203- 1214.  
32. Jordan MB, Allen CE, Weitzman S, Filipovich AH, McClain KL. How I treat 
hemophagocytic lymphohistiocytosis. Blood . 2011;118(15):4041- 4052.  
33. Henter JI, Arico M, Egeler RM, et al. HLH -94: a treatment protocol for 
hemophagocytic  lymphohistiocytosis.  HLH study  Group of the Histiocyte  Society.  Med 
Pediatr Oncol . 1997;28(5):342- 347. 
34. Bleesing J, Prada A, Siegel DM, et al. The diagnostic significance of soluble 
CD163 and soluble interleukin- 2 receptor alpha- chain in macrophage activati on 
syndrome and untreated new -onset systemic juvenile idiopathic arthritis. Arthritis 
Rheum . 2007;56(3):965- 971. 
46 | P a ge   17. APPENDIX A 
 
POTENTIAL CYP3A4 INTERACTIONS  
 
CYP3A4 Substrates 
Albuterol 
Alfentanil 
Alprazolam 
Amiodarone 
Amlodipine 
Amprenavir Aprepitant 
Aripiprazole 
Atazanavir 
Atorvastatin 
Benzphetamine 
Bisoprolol 
Bortezomib Bosentan 
Bromazepam 
Bromocriptine 
Budesonide 
Buprenorphine Buspirone 
Busulfan 
Carbamazepine 
Cerivastatin 
Chlordiazepoxide 
Chloroquine Chlorpheniramine Cilostazol 
Cisapride 
Citalopram 
Clarithromycin 
Clobazam Clonazepam 
Clorazepate 
Cocaine 
Colchicine 
Conivaptan 
Cyclophosphamide 
Cyclosporine Dantrolene 
Dapsone  
Dasatinib (1) 
Delvirdine 
Diazepam  Dihydroergotamine 
Diltiazem 
Disopyramide 
Docetaxel  
Doxepin 
Doxorubicin 
Doxycycline 
Efavirenz 
Eletriptan 
Enalapril Eplerenone 
Ergoloid  mesylates 
Ergonovine Ergotamine 
Erythromycin Escitalopram 
Estradiol 
Estrogens,  
conj.,  synthetic 
Estrogens,  
conj.,  equine 
Estrogens,  
conj.,  esterified 
Estrone 
Estropipate 
Ethinyl estradiol 
Ethosuximide 
Etoposide 
Exemastane 
Felbamate Felodipine 
Fentanyl 
Flurazepam 
Flutamide 
Fluticasone 
Fosamprenavir 
Gefitinib Haloperidol 
Ifosfamide 
Imatinib 
Indinavair 
Irinotecan  Isosorbide 
Isosorbide, dinitrate  
Isosorbide mononitrate Isradipine  
Itraconazole Ketamine 
Ketoconazole 
Lansoprazole 
Letrozole 
Levonorgestrel 
Lidocaine Losartan 
Lovastatin  
Medroxyprogesterone 
Mefloquine 
Mestranol  
Methadone 
Methylergonovine 
Methysergide 
Miconazole 
Midazolam 
Miglustat 
Mirtaz apine 
Modafinil 
Montelukast 
Moricizine 
Nateglinide 
Nefazodone 
Nelfinavir Nevirapine 
Nicardipine 
Nifedipine 
Nimodipine 
Nisoldipine 
Norethindrone 
Norgestrel Ondansetron 
Paclitaxel 
Pergolide 
Phencyclidine 
Pimozide 
Pipotiazine 
Primaquine  Progesterone 
Quetiapin e 
Quinidine Rabeprazole 
Ranolazine 
Repaglinide Rifabutin 
Ritonavir 
Salmetrol 
Saquinavir 
Sibutramine 
Sildenafil 
Simvastatin Sirolimus 
Spiramycin 
Sufentanil 
Sunitinib 
Tacrolimus Tamoxifen 
Tamsulosin 
Telithromycin 
Teniposide 
Tetracycline 
Theophylline 
Tiagabin e 
Ticlopidine 
Tipranavir 
Tolterodine 
Toremifene 
Trazodone Triazolam 
Trimethoprim 
Trimipramine 
Troleandomycin 
Vardenafil 
Venlafaxine 
Verapamil Vinblastine 
Vincristine 
Vinorelbine 
Zolpidem 
Zonisamide 
Zopiclone  
47 | P a ge   APPENDIX A (continued) 
POTENTIAL CYP3A4 INTERACTIONS  
CYP3A4 Inhibitors 
Acetaminophen 
Acetazolamide 
Amiodarone 
Amlodipine Amprenavir 
Anastrozole 
Aprepitant 
Atazanavir 
Atorvastatin 
Azelastine 
Azithromycin Betamethasone 
Bortezomib 
Bromocriptine 
Caffeine 
Cerivastatin 
Chloramphenicol 
Chlorzoxa zone 
Cimetidine 
Ciprofloxacin 
Cisapride 
Clarithromycin 
Clemastine Clofazimine 
Clotrimazole 
Clozapine 
Cocaine 
Conivaptan  
Cyclophosphamide 
Cyclosporine Danazol  
Dasatinib (1) Delvirdine Desipramine 
Dexmedetomidine 
Diazepam  Diclofenac 
Dihydroergotamine 
Diltiazem Disulfiram Docetaxel 
Doxorubicin 
Doxycycline 
Drospirenone 
Efavirenz 
Enoxacin 
Entacapone Ergotamine 
Erythromycin 
Ethinyl estradiol 
Etoposide 
Felodipine Fentanyl 
Fluconazole 
Fluoxetine 
Fluvastatin 
Fluvoxamine 
Fosamprenavir 
Glyburide Grapefruit Juic e(2) 
Haloperidol Hydralazine 
Ifosfamide 
Imatinib  
Indinavair 
Irbesartan 
Isoniazid 
Isradipine 
Itraconazole 
Ketoconazole 
Lansoprazole Lidocaine  Lomustine 
Losartan 
Lovastatin 
Mefloquine Mestranol 
Methadone 
Methimazole 
Methoxsalen  
Methylprednisolone 
Metronidazo le 
Miconazole 
Midazolam 
Mifepristone 
Mirtazapine 
Mitoxantrone 
Modafinil Nefazodone 
Nelfinavir 
Nevirapine 
Nicardipine 
Nifedipine Nisoldipine 
Nizatidine 
Norfloxacin 
Olanzapine 
Omeprazole 
Orphenadrine 
Oxybutynin Paroxetine 
Pentamidine 
Pergolide 
Phencyclidine 
Pilocarapine Pimozide 
Pravastatin 
Prednisolone  Primaquine 
Progesterone 
Propofol 
Propoxyphene Quinidine 
Quinine 
Quinupristin 
Rabeprazole 
Ranolazine 
Risperidone 
Ritonavir Saquinavir 
Selegiline 
Sertraline 
Sildenafil 
Sirolimus Sulconazole 
Tacrolimus 
Tamoxifen 
Telithromycin 
Teniposide 
Testosterone 
Tetracycl ine 
Ticlopidine 
Tranylcypromine 
Trazodone 
Troleandomycin 
Valproic Acid Venlafaxine 
Verapamil 
Vinblastine 
Vincristine 
Vinorelbine 
Voriconazole 
Zafirlukast Ziprasidone  
48 | P a ge   APPENDIX A (continued) 
POTENTIAL CYP3A4 INTERACTIONS  
 
CYP3A4 Inducers  
Aminoglutethimide 
Carbamazepine 
Fosphenytoin 
Nafcillin  Nevirapine 
Oxcarbazepine 
Pentobarbital  
Phenobarbital  Phenytoin 
Primidone 
Rifabutin  
Rifampin  Rifapentine  
St. John’s Wort (3)  
 
 
Note: Adapted from Cytochrome P450 Enzymes: Substrates, Inhibitors, and Inducers. In: Lacy CF, Armstrong 
LL, Goldman MP, Lance LL eds. Drug Information Handbook 15TH ed. Hudson, OH; LexiComp Inc. 2007: 
1899- 1912.  
Only major substrates and effective inducers are listed.  
Additional information for drug interactions with cytochro me P450 isoenzymes can be found at 
http://medicine.iupui.edu/flockhart/.  
 
(1) Investigator’s Brochure: Dasatinib (BMS 354825). Bristol -Myers Squibb. October  2006.  
 
(2) Malhotra et al. (2001). Clin Pharmacol Ther.  69:14- 23. 
 
(3) Mathijssen et al. (2002). J Natl Cancer Inst.  94:1247- 1249.  
 
(4) Frye et al. (2004). Clin Pharmacol Ther. 76:323- 329. 
 
Updated on May 1, 2007  